These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 22327795)

  • 1. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial.
    Kaseb AO; Garrett-Mayer E; Morris JS; Xiao L; Lin E; Onicescu G; Hassan MM; Hassabo HM; Iwasaki M; Deaton FL; Abbruzzese JL; Thomas MB
    Oncology; 2012; 82(2):67-74. PubMed ID: 22327795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study.
    Hsu CH; Kang YK; Yang TS; Shun CT; Shao YY; Su WC; Sandoval-Tan J; Chiou TJ; Jin K; Hsu C; Cheng AL
    Oncology; 2013; 85(1):44-52. PubMed ID: 23838576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
    Oncologist; 2012; 17(1):13. PubMed ID: 22210086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.
    Philip PA; Mahoney MR; Holen KD; Northfelt DW; Pitot HC; Picus J; Flynn PJ; Erlichman C
    Cancer; 2012 May; 118(9):2424-30. PubMed ID: 21953248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease.
    Yau T; Wong H; Chan P; Yao TJ; Pang R; Cheung TT; Fan ST; Poon RT
    Invest New Drugs; 2012 Dec; 30(6):2384-90. PubMed ID: 22402942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma.
    Govindarajan R; Siegel E; Makhoul I; Williamson S
    Am J Clin Oncol; 2013 Jun; 36(3):254-7. PubMed ID: 22643560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
    Johnson BE; Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Lin CY; Marsland T; Patel T; Polikoff J; Rubin M; White L; Yang JC; Bowden C; Miller V
    J Clin Oncol; 2013 Nov; 31(31):3926-34. PubMed ID: 24101054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.
    Thomas MB; Garrett-Mayer E; Anis M; Anderton K; Bentz T; Edwards A; Brisendine A; Weiss G; Siegel AB; Bendell J; Baron A; Duddalwar V; El-Khoueiry A
    Oncology; 2018; 94(6):329-339. PubMed ID: 29719302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
    Cohen EE; Davis DW; Karrison TG; Seiwert TY; Wong SJ; Nattam S; Kozloff MF; Clark JI; Yan DH; Liu W; Pierce C; Dancey JE; Stenson K; Blair E; Dekker A; Vokes EE
    Lancet Oncol; 2009 Mar; 10(3):247-57. PubMed ID: 19201650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.
    Chambers SK; Clouser MC; Baker AF; Roe DJ; Cui H; Brewer MA; Hatch KD; Gordon MS; Janicek MF; Isaacs JD; Gordon AN; Nagle RB; Wright HM; Cohen JL; Alberts DS
    Clin Cancer Res; 2010 Nov; 16(21):5320-8. PubMed ID: 21041183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.
    Thomas MB; Morris JS; Chadha R; Iwasaki M; Kaur H; Lin E; Kaseb A; Glover K; Davila M; Abbruzzese J
    J Clin Oncol; 2009 Feb; 27(6):843-50. PubMed ID: 19139433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
    Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.
    Lubner SJ; Mahoney MR; Kolesar JL; Loconte NK; Kim GP; Pitot HC; Philip PA; Picus J; Yong WP; Horvath L; Van Hazel G; Erlichman CE; Holen KD
    J Clin Oncol; 2010 Jul; 28(21):3491-7. PubMed ID: 20530271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.
    Bukowski RM; Kabbinavar FF; Figlin RA; Flaherty K; Srinivas S; Vaishampayan U; Drabkin HA; Dutcher J; Ryba S; Xia Q; Scappaticci FA; McDermott D
    J Clin Oncol; 2007 Oct; 25(29):4536-41. PubMed ID: 17876014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma.
    Casak SJ; Donoghue M; Fashoyin-Aje L; Jiang X; Rodriguez L; Shen YL; Xu Y; Jiang X; Liu J; Zhao H; Pierce WF; Mehta S; Goldberg KB; Theoret MR; Kluetz PG; Pazdur R; Lemery SJ
    Clin Cancer Res; 2021 Apr; 27(7):1836-1841. PubMed ID: 33139264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
    Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
    J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: a single-arm meta-analysis based on prospective studies.
    He L; Deng H; Lei J; Yi F; Li J; Fan X; Wei Y; Xu J; Zhang W
    BMC Cancer; 2019 Mar; 19(1):276. PubMed ID: 30922256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial.
    Hainsworth JD; Spigel DR; Sosman JA; Burris HA; Farley C; Cucullu H; Yost K; Hart LL; Sylvester L; Waterhouse DM; Greco FA
    Clin Genitourin Cancer; 2007 Dec; 5(7):427-32. PubMed ID: 18272024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.